Retour à l'accueil - Logo CERMN

EA 4258 | Centre d'études et de recherche sur le médicament de Normandie

Accueil > Production scientifique > Publications


Publications 2021

(232)     Bourafai-Aziez, A.; Benabderrahmane, M.; Paysant, H.; Weiswald, L.; Poulain, L.; Carlier, L.; Ravault, D.; Jouanne, M.; Coadou, G.; Oulyadi, H.; Voisin-Chiret, A.-S.; Sopková-de Oliveira Santos, J.; Sebban, M. Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1. Drug Des. Devel. Ther. 2021, Volume 15 (October), 5035–5059.

(231)     Helesbeux, J.; Carro, L.; McCarthy, F. O.; Moreira, V. M.; Giuntini, F.; O’Boyle, N.; Matthews, S. E.; Bayraktar, G.; Bertrand, S.; Rochais, C.; Marchand, P. 29th Annual GP2A Medicinal Chemistry Conference. Pharmaceuticals 2021, 14 (12), 1278.

(230)     Benabderrahmane, M.; Bureau, R.; Voisin-Chiret, A. S.; Santos, J. S. O. Cryptic Pockets Repository through Pocket Dynamics Tracking and Metadynamics on Essential Dynamics Space: Applications to Mcl-1. J. Chem. Inf. Model. 2021, 61 (11), 5581–5588.

(229)     Vera, G.; Mangeant, R.; Stiebing, S.; Berhault, Y.; Fabis, F.; Cailly, T.; Collot, V. Thiofunctionalization of Electron‐Rich Heteroarenes through Magnesiation and Trapping with Octasulfur. Adv. Synth. Catal. 2021, 363 (22), 5099–5105.

(228)     Paysant, H.; Hedir, S.; Justaud, F.; Weiswald, L. B.; El Dine, A. N.; Soulieman, A.; Hachem, A.; Elie, N.; Brotin, E.; Denoyelle, C.; Bignon, J.; Roussi, F.; Jouanne, M.; Tasseau, O.; Roisnel, T.; Voisin-Chiret, A. S.; Grée, R.; Levoin, N.; Poulain, L. Structural Revision of the Mcl-1 Inhibitor MIM1: Synthesis and Biological Studies on Ovarian Cancer Cells with Evaluation of Designed Analogues. Org. Biomol. Chem. 2021, 19 (41), 8968–8987.

(227)     Ceramella, J.; Groo, A.-C.; Iacopetta, D.; Séguy, L.; Mariconda, A.; Puoci, F.; Saturnino, C.; Leroy, F.; Since, M.; Longo, P.; Malzert-Fréon, A.; Sinicropi, M. S. A Winning Strategy to Improve the Anticancer Properties of Cisplatin and Quercetin Based on the Nanoemulsions Formulation. J. Drug Deliv. Sci. Technol. 2021, 66 (August), 102907.

(226)     Séguy, L.; Guyon, L.; Maurel, M.; Verdié, P.; Davis, A.; Corvaisier, S.; Lisowski, V.; Dallemagne, P.; Groo, A.; Malzert-Fréon, A. Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer’s Disease Treatment. Pharmaceutics 2021, 13 (10), 1626.

(225)     Rochoux, Q.; Sopkova-de Oliveira Santos, J.; Marcelli, C.; Rovelet-Lecrux, A.; Chevallier, V.; Dutheil, J.; Leclercq, S.; Boumédiene, K.; Baugé, C.; Aury-Landas, J. Description of Joint Alterations Observed in a Family Carrying p.Asn453Ser COMP Variant: Clinical Phenotypes, In Silico Prediction of Functional Impact on COMP Protein and Stability, and Review of the Literature. Biomolecules 2021, 11 (10), 1460.

(224)     Zipfel, P.; Lalut, J.; Sopková-de Oliveira Santos, J.; Rochais, C.; Dallemagne, P. Aminothiaindanone as an Accessible Scaffold for a Three-Point Chemical Diversity. Synthesis (Stuttg). 2021, 53 (20), 3799–3814.

(223)     Garrido, A.; Vera, G.; Delaye, P.-O.; Enguehard-Gueiffier, C. Imidazo[1,2-b]Pyridazine as Privileged Scaffold in Medicinal Chemistry: An Extensive Review. Eur. J. Med. Chem. 2021, 226, 113867.

(222)    Bosson-Vanga, H.; Primas, N.; Franetich, J.-F.; Lavazec, C.; Gomez, L.; Ashraf, K.; Tefit, M.; Soulard, V.; Dereuddre-Bosquet, N.; Le Grand, R.; Donnette, M.; Mustière, R.; Amanzougaghene, N.; Tajeri, S.; Suzanne, P.; Malzert-Fréon, A.; Rault, S.; Vanelle, P.; Hutter, S.; Cohen, A.; Snounou, G.; Roques, P.; Azas, N.; Lagardère, P.; Lisowski, V.; Masurier, N.; Nguyen, M.; Paloque, L.; Benoit-Vical, F.; Verhaeghe, P.; Mazier, D. A New Thienopyrimidinone Chemotype Shows Multistage Activity against Plasmodium Falciparum, Including Artemisinin-Resistant Parasites. Microbiol. Spectr. 2021, 9 (2), e00274-21.

(221)     Vigier, C.; Fossé, P.; Fabis, F.; Cailly, T.; Dubost, E. Controlled Access to C 1 ‐Symmetrical Cyclotriveratrylenes (CTVs) by Using a Sequential Barluenga Boronic Coupling (BBC) Approach. Adv. Synth. Catal. 2021, 363 (15), 3756–3761.

(220)     Dallemagne, P.; Rochais, C. 5-HT4R Modulators: A Patent Landscape. Pharm. Pat. Anal. 2021, 10 (4), 179–181.

(219)     Chrétien, B.; Jourdan, J.; Davis, A.; Fedrizzi, S.; Bureau, R.; Sassier, M.; Rochais, C.; Alexandre, J.; Lelong‐Boulouard, V.; Dolladille, C.; Dallemagne, P. Disproportionality Analysis in VigiBase as a Drug Repositioning Method for the Discovery of Potentially Useful Drugs in Alzheimer’s Disease. Br. J. Clin. Pharmacol. 2021, 87 (7), 2830–2837.

(218)     Daressy, F.; Malard, F.; Seguy, L.; Guérineau, V.; Apel, C.; Dumontet, V.; Robert, A.; Groo, A.; Litaudon, M.; Bignon, J.; Desrat, S.; Malzert-Fréon, A.; Wiels, J.; Lescop, E.; Roussi, F. Drimane Derivatives as the First Examples of Covalent BH3 Mimetics That Target MCL‐1. ChemMedChem 2021, 16 (11), 1789–1798.

(217)     Lecoutey, C.; Legay, R.; Davis, A.; Sopková-de Oliveira Santos, J.; Dallemagne, P.; Rochais, C. Development of Novel Potential Pleiotropic Compounds of Interest in Alzheimer’s Disease Treatment through Rigidification Strategy. Molecules 2021, 26 (9), 2536.

(216)     Smeralda, W.; Since, M.; Cardin, J.; Corvaisier, S.; Lecomte, S.; Cullin, C.; Malzert-Fréon, A. β-Amyloid Peptide Interactions with Biomimetic Membranes: A Multiparametric Characterization. Int. J. Biol. Macromol. 2021, 181, 769–777.

(215)     Menelle, P.; Quintin, J.; Cottet, K.; Fromentin, Y.; Dupont, J.; Lallemand, M.-C.; Buisson, D. Biotransformation of Guttiferones, Symphonia Globulifera Metabolites, by Bipolaris Cactivora , an Endophytic Fungus Isolated from Its Leaves. Org. Biomol. Chem. 2021, 19 (6), 1378–1385.

(214)     Ceyzériat, K.; Gloria, Y.; Tsartsalis, S.; Fossey, C.; Cailly, T.; Fabis, F.; Millet, P.; Tournier, B. B. Alterations in Dopamine System and in Its Connectivity with Serotonin in a Rat Model of Alzheimer’s Disease. Brain Commun. 2021, 3 (2), fcab029.

(213)     Guieu, B.; Jourdan, J.-P.; Dreneau, A.; Willand, N.; Rochais, C.; Dallemagne, P. Desirable Drug–Drug Interactions or When a Matter of Concern Becomes a Renewed Therapeutic Strategy. Drug Discov. Today 2021, 26 (2), 315–328.

(212)     Salas-Ambrosio, P.; Tronnet, A.; Since, M.; Bourgeade-Delmas, S.; Stigliani, J.; Vax, A.; Lecommandoux, S.; Dupuy, B.; Verhaeghe, P.; Bonduelle, C. Cyclic Poly(α-Peptoid)s by Lithium Bis(Trimethylsilyl)Amide (LiHMDS)-Mediated Ring-Expansion Polymerization: Simple Access to Bioactive Backbones. J. Am. Chem. Soc. 2021, 143 (10), 3697–3702.

(211)     Jouanne, M.; Oddoux, S.; Noël, A.; Voisin-Chiret, A. S. Nutrient Requirements during Pregnancy and Lactation. Nutrients 2021, 13 (2), 692.

(210)     Guyon, L.; Groo, A.-C.; Malzert-Fréon, A. Relevant Physicochemical Methods to Functionalize, Purify, and Characterize Surface-Decorated Lipid-Based Nanocarriers. Mol. Pharm. 2021, 18 (1), 44–64.

(209)     Guieu, B.; Lecoutey, C.; Legay, R.; Davis, A.; Sopkova de Oliveira Santos, J.; Altomare, C. D.; Catto, M.; Rochais, C.; Dallemagne, P. First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer’s Disease. Molecules 2021, 26 (1), 80.

(208)     Toublet, F.-X.; Lalut, J.; Hatat, B.; Lecoutey, C.; Davis, A.; Since, M.; Corvaisier, S.; Freret, T.; Oliveira Santos, J. S.; Claeysen, S.; et al. Pleiotropic Prodrugs: Design of a Dual Butyrylcholinesterase Inhibitor and 5-HT6 Receptor Antagonist with Therapeutic Interest in Alzheimer’s Disease. Eur. J. Med. Chem. 2021, 210, 113059.

(207)     Clergé, A.; Le Goff, J.; Lopez-Piffet, C.; Meier, S.; Lagadu, S.; Vaudorne, I.; Babin, V.; Cailly, T.; Delépée, R. Investigation by Mass Spectrometry and 32P Post-Labelling of DNA Adducts Formation from 1,2-Naphthoquinone, an Oxydated Metabolite of Naphthalene. Chemosphere 2021, 263, 128079.

Télécharger la page

Dernière modification : 15 dcembre 2021

Université de Caen Normandie
CERMN Centre détudes et de recherche sur le médicament de Normandie
Boulevard Becquerel | 14032 Caen Cedex | France